8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Feb 26, 2026·SEC
Revelation Biosciences, Inc.(REVB)Earnings, Financials & Key Ratios
REVB•NASDAQ
$0.98
Price updated Jun 27, 2026
AboutRevelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.Show more
- Revenue$0
- EBITDA-$9M-13.8%
- Net Income-$9M+40.7%
- EPS (Diluted)-23.95+72.7%
- ROE-131.38%+50.4%
REVB Price & Volume
Revelation Biosciences, Inc. (REVB) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Drive Persistent Equity Dilution
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
"Revelation Biosciences remains a pre-commercial clinical-stage entity characterized by a high-burn operational model that necessitates frequent reliance on external capital. The company's lack of consistent revenue, evidenced by the $3.1 million operating loss in 2026Q1, underscores the binary risk profile inherent in its therapeutic pipeline. Investors should monitor the rapid depletion of cash reserves, which fell to $10.7 million in 2025Q4, as this trajectory suggests a high probability of future dilutive financing events to sustain ongoing research and development."
Verdict Logic
the company's reliance on equity-linked financing to cover a $3.3 million quarterly free cash flow burn creates a significant dilution overhang for shareholders.
REVB Growth Metrics
Revelation Biosciences, Inc. (REVB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87.19%
Return on Capital
10 Years-935.37%
5 Years-994.11%
3 Years-164.07%
Last Year-126.93%
Peers Comparison
Key metrics vs top competitors for Revelation Biosciences, Inc. (REVB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.98 | $3.14M | -0.04 | — | — | -131.38% | — | |
| $8.75 | $2.03B | 14.58 | 19.63% | 32.43% | 38.97% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $74.96 | $8.89B | 29.28 | 37.55% | 23.13% | 126.27% | — | |
| $8.88 | $1.46B | 3.50 | 64.69% | -14.73% | — | — |
Compare REVB vs Peers
Revelation Biosciences, Inc. (REVB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
REVB SEC Filings & Documents
Revelation Biosciences, Inc. (REVB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when REVB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
REVB Frequently Asked Questions
Revelation Biosciences, Inc. (REVB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is REVB profitable?
Revelation Biosciences, Inc. (REVB) reported a net loss of $9.9M for fiscal year 2025.
Dividend & Returns
What is REVB's return on equity?
Revelation Biosciences, Inc. (REVB) has a return on equity (ROE) of -131.4%. Negative ROE indicates the company is unprofitable.
What is Revelation Biosciences, Inc.'s free cash flow?
Revelation Biosciences, Inc. (REVB) had negative free cash flow of $8.8M in fiscal year 2025, likely due to heavy capital investments.